On Thursday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Lumber Liquidators Holdings Inc (NYSE:LL), TIM Participacoes SA (ADR) (NYSE:TSU), Affymetrix, Inc (NASDAQ:AFFX), VIVUS, Inc (NASDAQ:VVUS)
Lumber Liquidators Holdings Inc (NYSE:LL)’s shares dwindled -6.18%, and closed at $29.89. The stock has price to sale ratio of 0.77, however, price to book ratio is 2.44. With recent decline, the year-to-date (YTD) performance reflected a -54.92% decline below last year. During the past month the stocks lose -40.96%, bringing three-month performance to -53.53% and six-month performance to -47.16%. The mean recommendation of analysts for this stock is 47.16. (where 1=Buy, 5=Sale).
Lumber Liquidators Holdings, Inc., together with its subsidiaries, operates as a multi-channel specialty retailer of hardwood flooring, and hardwood flooring enhancements and accessories. It primarily offers solid and engineered hardwood products; laminate floorings; bamboo floor products, cork floorings, and vinyl plank flooring; wood flooring moldings; butcher block kitchen countertops, and staircase treads and risers; and accessories, such as sealers, adhesives, and underlayment’s, in addition to flooring tools and floor cleaning supplies. The company offers its products primarily under the Bellawood and Morning Star Bamboo brands. It operates through various sales channels, such as stores, call center, and catalogs, in addition to through its Website, lumberliquidators.com. The company primarily serves the homeowner, or a contractor on behalf of a homeowner. As of December 31, 2014, it operated 352 stores in 46 states in the United States and Canada. The company was founded in 1994 and is headquartered in Toano, Virginia.
TIM Participacoes SA (ADR) (NYSE:TSU), declined -5.64%, and closed at $16.91, hitting new 52-week low of $16.77. The company holds the market capitalization of $8.48B. For the last twelve months, the stock was able to keep return on equity at 10.50%, while return on assets at 5.60%, in response to its return on investment at 9.20%. Its 20-day moving average declined -10.92%, below 50-day moving average of -19.72%, below 200-day moving average of -30.98% from the latest market price of $16.91. The mean recommendation of analysts for this stock is 2.40.(where 1=Buy, 5=Sale).
TIM Participaes S.A., through its subsidiaries, provides telecommunication services in Brazil. The company offers mobile, fixed, and long distance telephony; data transmission; and Internet services. It provides prepaid; post paid; and various value-added services, counting short message services or text messaging, multimedia messaging services, push-mail, Blackberry services, video call, turbo mail, WAP downloads, Web browsing, business data solutions, songs, games, TV access, voicemail, conference calling, chats, and other content and services. The company also offers co-billing services to other telecommunication service providers; and sells various mobile handsets and accessories through its dealer network, which comprises its own stores, exclusive franchises, authorized dealers, and department stores.
Affymetrix, Inc (NASDAQ:AFFX), dipped -5.51%, and closed at $12.00. The stock has the beta value of 0.53, and its volatility for the week is 3.01%, while for the month it is 2.80%. The company has the market capitalization of $896.64M. The company holds the book value per share of 3.68, whereas cash per share is 1.07. Price to book ratio remained 2.57, while price to sale ratio is 3.26. Analysts mean recommendation for the stock is said to be 2.90 (where 1=Buy, 5=sale).
Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry.
VIVUS, Inc (NASDAQ:VVUS), dropped -4.60%, and closed at $2.49.The company has the market capitalization of $271.13M. The beta value of the stock is 1.14. On the other hand the stock’s volatility for the week is 5.88%, and for the month is 6.71%. The stock’s price to book ratio is 3.11, however price to sale ratio is 2.26. Analyst’s mean recommendation regarding this stock is 3.30. (where 1=Buy, 5=Sale).
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and raised physical activity for chronic weight administration in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has accomplished Phase II studies for the treatment of obstructive sleep apnea and diabetes, in addition to for other obesity-related diseases, counting nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
